Transcode Therapeutics, Inc.

TransCode is a clinical-stage company focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers. Its primary therapeutic candidate is TTX-MC138, an antisense inhibitor targeting an oncogenic microRNA, which has completed a Phase 1a clinical trial. The company also researches and develops other RNA-targeted candidates, a cancer vaccine, and an oncolytic immunotherapy platform. On October 8, 2025, TransCode acquired 100% of ABCJ, LLC from DEFJ, LLC. ABCJ, LLC was previously an indirect wholly-owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., listed on the Main Board of the Hong Kong Stock Exchange. As part of this acquisition, TransCode issued 1,152.9568 shares of its Series A Non-Voting Convertible Preferred Stock to DEFJ, with each share convertible into 10,000 shares of common stock. ABCJ, LLC owns 100% of Polynoma, LLC, a San Diego, California-based immuno-oncology biopharmaceutical company. Polynoma develops Seviprotimut-L, an investigational polyvalent antigen vaccine designed to reduce cancer recurrence in patients with stage IIB and IIC melanoma who have limited treatment options. Seviprotimut-L has been safely administered to over 1,000 patients in clinical trials. TransCode plans to develop both TTX-MC138 and Seviprotimut-L, initially prioritizing TTX-MC138 for a planned Phase 2a clinical trial. The company also intends to conduct preclinical research combining Seviprotimut-L and TTX-MC138 to explore potential synergies, particularly for addressing micrometastases in stage IIB and IIC melanoma patients.